TELO - Telomir Pharmaceuticals Corp Total Debt to Capital

Telomir Pharmaceuticals (TELO) is a biopharmaceutical project developing small molecules to slow aging by targeting telomeres. This price chart shows that Telomir Pharmaceuticals (TELO) shares demonstrate a 0.03 metric, linking precision medicine innovations with management's efforts to gather preclinical data. The absence of a commercial product leaves the company dependent on external capital, eliminating its ability to independently influence market pricing.

To assess the fundamental stability of Telomir Pharmaceuticals (TELO), investors must analyze the balance between borrowed funds and equity assets. The history of the total debt-to-equity ratio reflects the degree of financial leverage: while a decreasing coefficient minimizes bankruptcy risks, moderate debt is essential for scaling biotechnological anti-aging developments and commercializing unique formulas.